List of Excipients in Branded Drug GAVISCON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	GAVISCON	aluminum hydroxide and magnesium carbonate	0135-0098	ALGINIC ACID
Haleon US Holdings LLC	GAVISCON	aluminum hydroxide and magnesium carbonate	0135-0098	CALCIUM STEARATE
Haleon US Holdings LLC	GAVISCON	aluminum hydroxide and magnesium carbonate	0135-0098	MANNITOL
Haleon US Holdings LLC	GAVISCON	aluminum hydroxide and magnesium carbonate	0135-0098	SODIUM BICARBONATE
Haleon US Holdings LLC	GAVISCON	aluminum hydroxide and magnesium carbonate	0135-0098	SORBITOL
Haleon US Holdings LLC	GAVISCON	aluminum hydroxide and magnesium carbonate	0135-0098	STARCH, CORN

Gaviscon Excipient Strategy, Formulation IP and Commercial Opportunities

Last updated: September 15, 2026

Gaviscon’s commercial value depends on formulation architecture rather than a single active pharmaceutical ingredient. The brand combines antacid salts with alginate or other raft-forming systems in selected markets. Its strongest opportunities are sugar-free liquids, low-sodium products, chewable formats, improved sensory profiles, pediatric and pregnancy-oriented positioning, and manufacturing platforms that preserve raft performance across global formulations.

The principal commercial constraint is that Gaviscon is primarily an established over-the-counter brand. In many markets, competing products can reproduce the therapeutic concept with different excipient systems. Differentiation therefore depends on product performance, consumer experience, regulatory compliance, trademark protection, manufacturing consistency and channel execution.

What active ingredients and excipients are used in Gaviscon?

Gaviscon formulations differ materially by country, dosage form and product variant. The UK and U.S. products illustrate the divergence.

Market or product family	Principal actives	Functional formulation system	Common excipient categories
UK Gaviscon Original liquid	Sodium alginate, sodium bicarbonate, calcium carbonate	Alginate raft plus acid neutralization	Suspending agents, sweeteners, preservatives, flavor, water
UK Gaviscon Advance	Higher alginate load with potassium bicarbonate	More concentrated raft-forming barrier	Carbomer or related rheology modifiers, sweeteners, preservatives, flavor, water
UK chewable tablets	Alginate and carbonate/bicarbonate salts, depending on product	Chewable antacid and raft system	Binders, lubricants, sweeteners, flavors, compression aids
U.S. Gaviscon products	Aluminum hydroxide, magnesium carbonate and sodium bicarbonate in commonly marketed products	Antacid neutralization and physical barrier effects	Flavor, sweeteners, binders, lubricants and tablet or suspension excipients
Sugar-free variants	Same or similar actives by market	Raft or antacid performance without sucrose	Polyols, high-intensity sweeteners, viscosity modifiers, preservatives

The UK product information identifies sodium alginate, bicarbonate salts and calcium carbonate as core active ingredients in major Gaviscon liquid products. The U.S. product architecture is different and is generally based on aluminum hydroxide, magnesium carbonate and sodium bicarbonate under the U.S. antacid regulatory framework.[1-3]

Excipients are not interchangeable. Their concentration affects raft formation, viscosity, sedimentation, pourability, taste, tablet hardness, disintegration, microbial stability and the product’s ability to remain uniform during shelf life.

How does the Gaviscon raft-forming mechanism affect excipient selection?

The raft system is created when alginate interacts with gastric acid and carbonate or bicarbonate salts. Carbon dioxide can become entrapped in the hydrated alginate matrix, producing a buoyant barrier at the gastric contents surface. Calcium ions can strengthen alginate networks through ionic cross-linking.

This mechanism creates several excipient requirements:

1. The alginate must hydrate rapidly enough to produce a coherent raft.
2. The carbonate or bicarbonate system must generate gas at the intended rate.
3. The formulation must remain physically stable before administration.
4. The raft must resist premature breakdown under gastric agitation.
5. The product must retain acceptable taste and mouthfeel.

Alginate grade and molecular weight

Alginate grade is a central formulation variable. Molecular weight, mannuronic-to-guluronic acid ratio, viscosity and particle size influence hydration and gel strength. Higher-viscosity alginates can improve raft strength but create manufacturing and dosing problems, including poor pourability, nozzle blockage and unacceptable mouthfeel.

A practical commercial strategy is to use a blended alginate system. A lower-viscosity grade can support rapid dispersion, while a higher-guluronic or higher-viscosity grade can improve network strength. Any change requires comparative testing because the active ingredient label may remain unchanged while the performance profile changes.

Carbomer and other rheology modifiers

Carbomer can improve suspension stability and control sedimentation in liquid products. It also affects pourability and the distribution of alginate throughout the dose. Excessive polymer loading can create a thick, stringy product that consumers perceive as difficult to swallow.

Other options include xanthan gum, cellulose derivatives, carrageenan and modified starches. Each presents a different balance between viscosity, shear recovery, acid compatibility, sensory profile and regulatory acceptability.

Carbonate and bicarbonate salts

Sodium bicarbonate contributes carbon dioxide generation but increases sodium exposure. Calcium carbonate can provide acid neutralization and calcium-mediated alginate strengthening. Potassium bicarbonate can reduce sodium content but introduces potassium considerations for label positioning and certain consumer groups.

The salt system also controls effervescence, raft density and gastric residence. A product with rapid gas generation may form a weaker or less persistent raft if the polymer network does not develop at the same rate.

What excipients are most commercially attractive for Gaviscon?

The most attractive excipient opportunities are those that solve a consumer or manufacturing problem without compromising the raft mechanism.

Sugar-free and low-sugar systems

Sugar-free products can expand use among consumers who monitor sugar intake. Suitable systems may combine sorbitol, xylitol, maltitol, sucralose, acesulfame potassium or saccharin, depending on jurisdiction and dosage form.

Polyols can improve bulk and mouthfeel but may cause gastrointestinal tolerance issues at higher exposure. High-intensity sweeteners reduce dose volume but can leave bitterness or metallic aftertaste. Flavor masking is especially important because alginate and carbonate salts can produce earthy, alkaline and mineral notes.

Low-sodium formulations

Sodium reduction is a clear product-development opportunity. Potential approaches include:

• Replacing part of sodium bicarbonate with potassium bicarbonate.
• Increasing the relative contribution of calcium carbonate.
• Using a stronger alginate system to reduce dependence on bicarbonate.
• Developing smaller-dose or concentrated products.
• Providing sodium-per-dose information in consumer-facing communications.

Any low-sodium formulation must preserve gas generation and raft performance. Potassium substitution also requires careful labeling and risk assessment for consumers with renal impairment or medicines that affect potassium handling.

Improved flavor and mouthfeel

Flavor systems can differentiate otherwise similar antacid products. Mint is strongly associated with existing Gaviscon products, but citrus, berry and neutral flavors may broaden consumer appeal.

The main flavor challenge is masking the interaction between alginate, bicarbonate, carbonate and metal-containing salts. Encapsulated flavors, cooling agents and bitterness blockers can improve acceptability. Flavor oil selection must also account for emulsion stability, preservative compatibility and packaging sorption.

Preservative systems

Liquid alginate products require microbial control. Common approaches include parabens, benzoates, sorbates or combinations with low water activity and hygienic manufacturing controls. Preservative choice affects pH, taste, regulatory status and compatibility with polymers.

Paraben-free systems may have marketing value, but replacement can increase formulation complexity. A preservative change must be evaluated with antimicrobial effectiveness testing, container-closure studies and in-use stability testing.

What formulations are protected by Gaviscon’s intellectual property?

Gaviscon’s defensibility is likely to rest more heavily on trademarks, formulation know-how, manufacturing controls and market history than on a single active patent covering the basic antacid concept.

Protection category	Commercial relevance	Typical durability
Gaviscon trademark	Brand recognition and pharmacy shelf position	Potentially renewable indefinitely
Product-specific formulation patents	May cover selected alginate, salt or dosage-form combinations	Limited term, generally 20 years from earliest non-provisional filing
Manufacturing know-how	Controls alginate hydration, suspension stability and raft performance	Potentially indefinite as trade secret
Packaging and device design	Supports dosing accuracy and product differentiation	Patent, design-right or trade-dress dependent
Regulatory dossiers and quality data	Raises practical entry costs	Dependent on jurisdiction and pathway
Advertising and consumer familiarity	Supports premium pricing and repeat use	Depends on market investment

A competitor can often avoid a formulation patent by changing alginate grade, carbonate ratio, polymer system, flavor, preservative or dosage form. The commercial barrier may still be substantial if the alternative does not match raft persistence, taste, stability and manufacturing yield.

Patent assessment should be product-specific. Gaviscon Original, Gaviscon Advance, chewable tablets and U.S. products should not be treated as a single patent family. Patent term, claim scope and enforceability also differ by jurisdiction.

What is the FDA regulatory status and Orange Book status of Gaviscon?

U.S. Gaviscon products are generally marketed as over-the-counter antacid products rather than as conventional prescription NDA products. The applicable U.S. framework is the FDA OTC monograph system for antacid products, subject to the permitted active ingredients, labeling and conditions of use.[3]

Because monograph OTC products are not typically approved under an individual NDA, they generally do not have an Orange Book listing comparable to an NDA drug. An abbreviated new drug application Paragraph IV pathway is therefore not the normal route for a competing product marketed under the same OTC monograph conditions.

Regulatory issue	Gaviscon implication
FDA pathway	OTC monograph pathway for qualifying products
Conventional NDA exclusivity	Generally not the principal commercial protection
Orange Book listing	Generally not expected for monograph-marketed products
Paragraph IV challenge	Usually not the principal competitive mechanism
Main regulatory risks	Active-ingredient compliance, labeling, quality, manufacturing and product-specific claims
Global variation	High; UK and EU products follow different medicine and self-care frameworks

In the UK, Gaviscon products are regulated under the applicable medicines framework and product-specific marketing authorizations. The Summary of Product Characteristics and patient information identify the active ingredients, excipients and permitted indications for each product.[1,2]

When does Gaviscon lose exclusivity?

There is no single Gaviscon exclusivity expiration date. The answer depends on the protection being analyzed.

• Basic antacid and alginate concepts are longstanding and broadly available.
• Patents covering older formulations may already have expired.
• Later patents can protect specific combinations, concentrations, dosage forms or manufacturing processes.
• The Gaviscon trademark can remain active through renewals.
• Regulatory exclusivity is product- and jurisdiction-specific.
• Trade secrets and manufacturing controls do not have a fixed statutory expiration if maintained confidentially.

For investors and competitors, the practical entry question is not simply whether an old formulation patent has expired. It is whether a new product can meet regulatory requirements and replicate the commercial performance of the branded product at acceptable cost.

Which companies are challenging or competing with Gaviscon?

Competition comes from several groups:

1. Alginate-based reflux products, including regional brands and private-label equivalents.
2. Conventional antacids based on calcium carbonate, magnesium hydroxide, aluminum hydroxide or bicarbonate.
3. Acid-suppression products such as proton pump inhibitors and H2-receptor antagonists.
4. Retailer-owned OTC products using similar active ingredients.
5. Gastroesophageal reflux products using barrier-forming polymers or raft technologies.

Competition is strongest where private-label manufacturers can offer equivalent active ingredients and a simpler dosage form. Gaviscon retains an advantage when consumers value the brand, prefer liquid products, or specifically seek a physical barrier product rather than acid neutralization alone.

What manufacturing and IP barriers affect generic Gaviscon entry?

The most important barriers are technical rather than statutory.

Suspension uniformity

Alginate liquids can sediment, flocculate or form viscosity gradients. A commercial product must deliver consistent active content throughout the bottle and remain pourable after storage.

Raft reproducibility

Small changes in alginate grade, particle size, salt ratio, mixing order or hydration time can alter raft volume and persistence. Scale-up from laboratory to commercial equipment is therefore material.

Carbon dioxide management

Gas generation affects filling, headspace, container pressure and product stability. Manufacturing conditions must control premature reaction before administration.

Packaging compatibility

High-viscosity liquids require suitable closures and dosing devices. Extractables, leachables, sorption and dispensing accuracy can affect both quality and consumer experience.

Supply-chain concentration

Pharmaceutical-grade alginate and specialty polymers may have fewer qualified suppliers than conventional antacid salts. Dual sourcing is valuable but can create performance differences that require comparability work.

How does Gaviscon compare with conventional antacids?

Attribute	Gaviscon-type raft product	Conventional antacid
Primary consumer proposition	Barrier formation plus acid neutralization	Acid neutralization
Key formulation driver	Alginate-polymer and carbonate interaction	Salt solubility, neutralizing capacity and palatability
Excipient complexity	Higher, particularly for liquids	Often lower
Technical entry barrier	Raft performance and suspension stability	Active content, taste and tablet quality
Differentiation potential	Stronger through dosage form and sensory design	More exposed to price competition
Main opportunity	Reflux-specific, sugar-free and improved-raft variants	Cheaper, faster, higher-strength antacid products

Gaviscon also compares favorably where consumers want immediate relief and a non-systemic physical barrier. Conventional antacids may have simpler manufacturing and lower cost, but they do not provide the same product narrative or formulation mechanism.

What licensing and commercial opportunities exist for Gaviscon excipient technology?

The strongest licensing opportunities are platform-based rather than brand-specific.

Alginate and polymer suppliers

Suppliers with pharmaceutical-grade alginates, controlled molecular-weight distributions or improved hydration profiles can license or co-develop differentiated raft systems.

Encapsulated flavor and taste-masking companies

A superior flavor system can support line extensions without changing the therapeutic concept. This is relevant for sugar-free, pediatric-adjacent and premium products.

Low-sodium formulation platforms

A validated sodium-reduction platform could support new regional products, particularly where consumers or regulators focus on sodium exposure.

Single-dose and portable formats

Stick packs, sachets, chewable tablets and orally disintegrating formats could improve convenience and support travel, workplace and nighttime use.

Private-label manufacturing

Contract manufacturers can compete by offering equivalent active systems with lower-cost packaging, localized flavors and retailer-specific branding. The principal challenge is demonstrating consistent raft performance and stable shelf life.

What generic launch scenarios exist for Gaviscon?

Scenario 1: Direct liquid copy

A competitor uses the same or similar alginate and carbonate system in a liquid bottle. This is the closest substitute but faces the greatest formulation-comparability challenge.

Scenario 2: Chewable tablet substitution

A competitor launches a tablet with similar active ingredients. It has lower shipping and packaging costs but may provide a different onset and raft profile.

Scenario 3: Private-label sugar-free product

A retailer introduces a lower-priced liquid or tablet using a similar active system and simpler branding. This is a realistic channel threat in mature OTC markets.

Scenario 4: Low-sodium premium product

A competitor uses potassium or calcium substitution, consumer-friendly sodium disclosure and a premium price. Regulatory labeling and potassium exposure become important constraints.

Scenario 5: Non-alginate reflux product

A competing barrier technology or acid-suppression product targets the same symptoms without reproducing the Gaviscon formulation. This creates category competition rather than direct generic substitution.

What is the revenue exposure from Gaviscon competition?

Revenue exposure is highest in products with:

• High retail price premiums over private label.
• Limited differentiation beyond active ingredients.
• Liquid dosage forms that are costly to manufacture or ship.
• High dependence on pharmacy recommendation.
• Concentrated distribution in mature, price-sensitive markets.
• No active formulation patent or regulatory exclusivity.

Revenue resilience is stronger where the brand has high consumer recognition, a distinctive raft claim, strong clinical communication, broad flavor and dosage-form coverage, and reliable global supply.

The most defensible commercial portfolio would combine a flagship raft product with lower-cost tablets, sugar-free liquids, single-dose sachets and a low-sodium variant. This structure allows the brand to address premium, convenience and value segments without relying on one formulation.

Key Takeaways

• Gaviscon’s central formulation asset is the alginate-based raft system used in major non-U.S. products.
• Excipients control raft strength, suspension stability, taste, viscosity, preservative performance and manufacturing yield.
• Gaviscon formulations vary by market; U.S. products commonly use a different antacid architecture from UK Gaviscon products.
• The main commercial opportunities are sugar-free liquids, low-sodium products, chewables, single-dose formats and improved taste systems.
• Gaviscon is generally an OTC monograph product in the United States, so Orange Book and Paragraph IV strategies are usually less relevant than for NDA drugs.
• Trademark, manufacturing know-how, consumer recognition and regulatory execution may provide greater commercial protection than legacy formulation patents.
• Private-label and regional alginate products are the most direct competitive threats.
• Any formulation change must be assessed against raft performance, sensory quality, microbial stability, container compatibility and local regulatory requirements.

FAQs About Gaviscon Excipient Strategy

Does Gaviscon contain an active pharmaceutical ingredient or only excipients?

Gaviscon contains active antacid and, in key markets, alginate ingredients. Excipients support suspension, taste, viscosity, preservation, tablet manufacture and product stability.

Why is sodium bicarbonate used in Gaviscon formulations?

Sodium bicarbonate can neutralize acid and generate carbon dioxide in the presence of acid. The gas can contribute to formation of a buoyant alginate raft. It also increases sodium content.

Can calcium carbonate replace sodium bicarbonate in a Gaviscon-type product?

Calcium carbonate can provide acid neutralization and calcium ions that influence alginate gel formation, but it does not replicate the gas-generation function of bicarbonate. A replacement requires reformulation and performance testing.

Are Gaviscon liquids difficult to manufacture?

They can be more challenging than conventional antacid tablets because manufacturers must control alginate hydration, viscosity, sedimentation, raft performance, microbial quality and dosing uniformity.

Is Gaviscon protected by a single global patent?

No. Protection must be assessed by product, formulation, jurisdiction and filing history. Trademark rights, product-specific patents, regulatory status and manufacturing know-how may each contribute to the commercial position.

References

1. Reckitt Benckiser Healthcare (UK) Limited. (2023). Gaviscon Advance aniseed oral suspension: Summary of product characteristics. Electronic Medicines Compendium.

2. Reckitt Benckiser Healthcare (UK) Limited. (2023). Gaviscon Original peppermint oral suspension: Summary of product characteristics. Electronic Medicines Compendium.

3. U.S. Food and Drug Administration. (2023). Antacid products for over-the-counter human use: Final monograph, 21 C.F.R. Part 331. Code of Federal Regulations.